title: Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
abstract: BACKGROUND
  Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB.
  
  
  RESULTS
  Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3-2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7-4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4-2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4-6.0]).
  
  
  CONCLUSIONS
  In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment. Please see later in the article for the Editors' Summary.
authors.affiliation: Bureau of Tuberculosis, New York, New York, United States of America.
authors.forename: Shama D
authors.initials: SD
authors.lastname: Ahuja
authors.forename: David
authors.initials: D
authors.lastname: Ashkin
authors.forename: Monika
authors.initials: M
authors.lastname: Avendano
authors.forename: Rita
authors.initials: R
authors.lastname: Banerjee
authors.forename: Melissa
authors.initials: M
authors.lastname: Bauer
authors.forename: Jamie N
authors.initials: JN
authors.lastname: Bayona
authors.forename: Mercedes C
authors.initials: MC
authors.lastname: Becerra
authors.forename: Andrea
authors.initials: A
authors.lastname: Benedetti
authors.forename: Marcos
authors.initials: M
authors.lastname: Burgos
authors.forename: Rosella
authors.initials: R
authors.lastname: Centis
authors.forename: Eward D
authors.initials: ED
authors.lastname: Chan
authors.forename: Chen-Yuan
authors.initials: CY
authors.lastname: Chiang
authors.forename: Helen
authors.initials: H
authors.lastname: Cox
authors.forename: Lia
authors.initials: L
authors.lastname: D'Ambrosio
authors.forename: Kathy
authors.initials: K
authors.lastname: DeRiemer
authors.forename: Nguyen Huy
authors.initials: NH
authors.lastname: Dung
authors.forename: Donald
authors.initials: D
authors.lastname: Enarson
authors.forename: Dennis
authors.initials: D
authors.lastname: Falzon
authors.forename: Katherine
authors.initials: K
authors.lastname: Flanagan
authors.forename: Jennifer
authors.initials: J
authors.lastname: Flood
authors.forename: Maria L
authors.initials: ML
authors.lastname: Garcia-Garcia
authors.forename: Neel
authors.initials: N
authors.lastname: Gandhi
authors.forename: Reuben M
authors.initials: RM
authors.lastname: Granich
authors.forename: Maria G
authors.initials: MG
authors.lastname: Hollm-Delgado
authors.forename: Timothy H
authors.initials: TH
authors.lastname: Holtz
authors.forename: Michael D
authors.initials: MD
authors.lastname: Iseman
authors.forename: Leah G
authors.initials: LG
authors.lastname: Jarlsberg
authors.forename: Salmaan
authors.initials: S
authors.lastname: Keshavjee
authors.forename: Hye-Ryoun
authors.initials: HR
authors.lastname: Kim
authors.forename: Won-Jung
authors.initials: WJ
authors.lastname: Koh
authors.forename: Joey
authors.initials: J
authors.lastname: Lancaster
authors.forename: Christophe
authors.initials: C
authors.lastname: Lange
authors.forename: Wiel C M
authors.initials: WC
authors.lastname: de Lange
authors.forename: Vaira
authors.initials: V
authors.lastname: Leimane
authors.forename: Chi Chiu
authors.initials: CC
authors.lastname: Leung
authors.forename: Jiehui
authors.initials: J
authors.lastname: Li
authors.forename: Dick
authors.initials: D
authors.lastname: Menzies
authors.forename: Giovanni B
authors.initials: GB
authors.lastname: Migliori
authors.forename: Sergey P
authors.initials: SP
authors.lastname: Mishustin
authors.forename: Carole D
authors.initials: CD
authors.lastname: Mitnick
authors.forename: Masa
authors.initials: M
authors.lastname: Narita
authors.forename: Philly
authors.initials: P
authors.lastname: O'Riordan
authors.forename: Madhukar
authors.initials: M
authors.lastname: Pai
authors.forename: Domingo
authors.initials: D
authors.lastname: Palmero
authors.forename: Seung-kyu
authors.initials: SK
authors.lastname: Park
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Pasvol
authors.forename: Jose
authors.initials: J
authors.lastname: Peña
authors.forename: Carlos
authors.initials: C
authors.lastname: Pérez-Guzmán
authors.forename: Maria I D
authors.initials: MI
authors.lastname: Quelapio
authors.forename: Alfredo
authors.initials: A
authors.lastname: Ponce-de-Leon
authors.forename: Vija
authors.initials: V
authors.lastname: Riekstina
authors.forename: Jerome
authors.initials: J
authors.lastname: Robert
authors.forename: Sarah
authors.initials: S
authors.lastname: Royce
authors.forename: H Simon
authors.initials: HS
authors.lastname: Schaaf
authors.forename: Kwonjune J
authors.initials: KJ
authors.lastname: Seung
authors.forename: Lena
authors.initials: L
authors.lastname: Shah
authors.forename: Tae Sun
authors.initials: TS
authors.lastname: Shim
authors.forename: Sonya S
authors.initials: SS
authors.lastname: Shin
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shiraishi
authors.forename: José
authors.initials: J
authors.lastname: Sifuentes-Osornio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Sotgiu
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Strand
authors.forename: Payam
authors.initials: P
authors.lastname: Tabarsi
authors.forename: Thelma E
authors.initials: TE
authors.lastname: Tupasi
authors.forename: Robert
authors.initials: R
authors.lastname: van Altena
authors.forename: Martie
authors.initials: M
authors.lastname: Van der Walt
authors.forename: Tjip S
authors.initials: TS
authors.lastname: Van der Werf
authors.forename: Mario H
authors.initials: MH
authors.lastname: Vargas
authors.forename: Pirett
authors.initials: P
authors.lastname: Viiklepp
authors.forename: Janice
authors.initials: J
authors.lastname: Westenhouse
authors.forename: Wing Wai
authors.initials: WW
authors.lastname: Yew
authors.forename: Jae-Joon
authors.initials: JJ
authors.lastname: Yim
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D016001:Confidence Intervals; D005260:Female; D006801:Humans; D008297:Male; D016017:Odds Ratio; D012008:Recurrence; D017211:Treatment Failure; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents